Buy Lupin, Says Investec After Stock Rating Upgrade; Share Price Target Hiked — What’s Driving Growth?
Investec has increased its Ebitda estimates for the financial years 2026 and 2027 by 23% and 10%, respectively, driven by a more optimistic forecast for the company’s US business.
The company’s US operations are experiencing strong growth, largely due to the performance of key products like Spiriva, gGle, and gFro. These products are making a significant contribution to Lupin’s revenue and profitability.
Lupin’s business in India is also performing well, showing consistent double-digit growth. The domestic market is a crucial part of the company’s overall strategy.
Investec also noted that Lupin is developing injectables, such as glucagon, Risperdal, liraglutide, and ganirelix. These products are seen as more sustainable despite some…
